18 Jun 2012, BioSpectrum Bureau , BioSpectrum
Singapore: China Nuokang Bio-Pharmaceutical, a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, announced that Mr Robert Tianruo Pu, the chief financial officer of the company, has tendered his resignation for personal reasons, effective June 30, 2012. Mr Felix Chungfai Wong, currently the company's finance director, will replace Mr Pu to serve as the chief financial officer. Upon his resignation, Mr Pu will remain with the Company as a consultant.
"Mr Pu has made significant contributions to Nuokang's growth and development since he joined in September 2008. We thank him for his leadership and dedication to the Company. We wish him all the best in his future endeavors," commented Mr Baizhong Xue, the company's chairman and chief executive officer.
Mr Felix Chungfai Wong joined Nuokang in February 2012 as its finance director. Mr Wong has three decades of experience in finance, management and accounting in the US and Greater China. He joined Nuokang from ITT, a company listed on the New York Stock Exchange, where he held various senior financial management positions. Prior to that, he held various senior finance positions across a broad range of industries, including finance manager of Roche (China) Investment, one of the world's leading pharmaceutical and diagnostics firms. He also has a decade of auditing experience in large multinational accounting firms in Hong Kong and Singapore. Mr Wong graduated from the Accountancy Faculty of the Hong Kong Polytechnic University and is a member of the Hong Kong Institute of Certified Public Accountants, the Association of Chartered Certified Accountants and the Institute of Chartered Accountants in England and Wales.